Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update.

Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA, Simon LS, Strand V, Williams DA, Arnold LM; OMERACT Fibromyalgia Working Group.

J Rheumatol. 2011 Jul;38(7):1487-95. doi: 10.3899/jrheum.110277.

2.

Fibromyalgia syndrome module at OMERACT 9: domain construct.

Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA; OMERACT Fibromyalgia Working Group.

J Rheumatol. 2009 Oct;36(10):2318-29. doi: 10.3899/jrheum.090367.

3.

Fibromyalgia syndrome.

Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, Chappell A, Choy E, Clauw D, Dadabhoy D, Gendreau M, Goldenberg D, Littlejohn G, Martin S, Perera P, Russell IJ, Simon L, Spaeth M, Williams D, Crofford L.

J Rheumatol. 2007 Jun;34(6):1415-25.

PMID:
17552068
4.

Societal and individual burden of illness among fibromyalgia patients in France: association between disease severity and OMERACT core domains.

Perrot S, Schaefer C, Knight T, Hufstader M, Chandran AB, Zlateva G.

BMC Musculoskelet Disord. 2012 Feb 17;13:22. doi: 10.1186/1471-2474-13-22.

5.

Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group.

Coates LC, Mumtaz A, Helliwell PS, Mease PJ, Callis-Duffin K, Krueger GG, McHugh NJ, Strand V, Gladman DD, FitzGerald O.

J Rheumatol. 2011 Jul;38(7):1496-501. doi: 10.3899/jrheum.110278.

PMID:
21724722
6.

Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11.

Coates LC, FitzGerald O, Mease PJ, Gladman DD, Strand V, Goel N, Campbell I, Krueger G, McHugh NJ, Helliwell PS.

J Rheumatol. 2014 Apr;41(4):782-91. doi: 10.3899/jrheum.131250. Epub 2014 Feb 1. Review.

PMID:
24488420
7.

Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome.

Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Glass JM, Simon LS, Martin SA, Strand CV, Williams DA, Mease PJ.

J Rheumatol. 2009 Oct;36(10):2330-4. doi: 10.3899/jrheum.090368.

8.

Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014.

Tillett W, Eder L, Goel N, De Wit M, Gladman DD, FitzGerald O, Campbell W, Helliwell PS, Gossec L, Orbai AM, Ogdie A, Strand V, McHugh NJ, Mease PJ.

J Rheumatol. 2015 Nov;42(11):2198-203. doi: 10.3899/jrheum.141156. Epub 2015 May 1. Review.

PMID:
25934828
9.

Do we need core sets of fibromyalgia domains? The assessment of fibromyalgia (and other rheumatic disorders) in clinical practice.

Wolfe F, Hassett AL, Katz RS, Michaud K, Walitt B.

J Rheumatol. 2011 Jun;38(6):1104-12. doi: 10.3899/jrheum.100511. Epub 2011 Feb 1.

PMID:
21285168
10.

Systematic review of discriminating power of outcome measures used in clinical trials of fibromyalgia.

Carville SF, Choy EH.

J Rheumatol. 2008 Nov;35(11):2094-105. Epub 2008 Sep 15. Review.

PMID:
18792996
11.

Fibromyalgia syndrome.

Mease PJ, Clauw DJ, Arnold LM, Goldenberg DL, Witter J, Williams DA, Simon LS, Strand CV, Bramson C, Martin S, Wright TM, Littman B, Wernicke JF, Gendreau RM, Crofford LJ.

J Rheumatol. 2005 Nov;32(11):2270-7.

PMID:
16265715
12.

Domains selection for patient-reported outcomes: current activities and options for future methods.

Tugwell PS, Petersson IF, Boers M, Gossec L, Kirwan JR, Rader T, Sanderson TC, van de Laar MA, Ueffing E, Witter JP.

J Rheumatol. 2011 Aug;38(8):1702-10. doi: 10.3899/jrheum.110389.

PMID:
21807789
13.

Development of responder definitions for fibromyalgia clinical trials.

Arnold LM, Williams DA, Hudson JI, Martin SA, Clauw DJ, Crofford LJ, Wang F, Emir B, Lai C, Zablocki R, Mease PJ.

Arthritis Rheum. 2012 Mar;64(3):885-94. doi: 10.1002/art.33360.

14.

Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10.

Machado PM, Landewé RB, van der Heijde DM.

J Rheumatol. 2011 Jul;38(7):1502-6. doi: 10.3899/jrheum.110279.

PMID:
21724723
15.

Multidimensional daily diary of fatigue-fibromyalgia-17 items (MDF-fibro-17): part 2 psychometric evaluation in fibromyalgia patients.

Li Y, Morris S, Cole J, Dube' S, Smith JAM, Burbridge C, Symonds T, Hudgens S, Wang W.

BMC Musculoskelet Disord. 2017 May 18;18(1):198. doi: 10.1186/s12891-017-1545-x.

16.

Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment.

Mease P.

J Rheumatol Suppl. 2005 Aug;75:6-21. Review. Erratum in: J Rheumatol Suppl. 2005 Oct;32(10):2063.

PMID:
16078356
18.

Balneotherapy for fibromyalgia at the Dead Sea.

Buskila D, Abu-Shakra M, Neumann L, Odes L, Shneider E, Flusser D, Sukenik S.

Rheumatol Int. 2001 Apr;20(3):105-8.

PMID:
11354556
19.

Toward characterization and definition of fibromyalgia severity.

Silverman S, Sadosky A, Evans C, Yeh Y, Alvir JM, Zlateva G.

BMC Musculoskelet Disord. 2010 Apr 8;11:66. doi: 10.1186/1471-2474-11-66.

20.

Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary.

Bartlett SJ, Bykerk VP, Cooksey R, Choy EH, Alten R, Christensen R, Furst DE, Guillemin F, Halls S, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Orbai AM, Pohl C, Voshaar MS, Woodworth TG, Bingham CO 3rd.

J Rheumatol. 2015 Nov;42(11):2185-9. doi: 10.3899/jrheum.141169. Epub 2015 Feb 15. Review.

Supplemental Content

Support Center